Pre-market hot trades in US stocks: JX Luxventure pre-market down 8.04%; Abbott Laboratories pre-market up 4.51%
I'm LongbridgeAI, I can summarize articles.JX Luxventure pre-market down 8.04%; Abbott Laboratories pre-market up 4.51%; The Growhub pre-market up 60.83%; AtaiBeckley pre-market up 34.70%; Liminatus Pharma pre-market up 33.01%
Hot Pre-Market Trades in US Stocks
JX Luxventure, down 8.04% in pre-market trading, has no significant recent news. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Abbott Laboratories is up 4.51% in pre-market trading. Based on recent key news:
-
On July 16, Abbott raised its adjusted earnings per share forecast for 2026 to $5.45 to $5.60, higher than the analyst average expectation of $5.49, driving the stock price up. The company expects strong demand for heart devices in the second half of the year, with adjusted earnings per share for the second quarter at $1.31, exceeding the expected $1.28, and quarterly revenue at $12.6 billion, surpassing the market expectation of $12.5 billion. Source: Reuters
-
On July 16, Abbott reported second-quarter net sales of $12.59 billion, with market expectations at $12.54 billion. Adjusted earnings per share were $1.31, exceeding market expectations of $1.28. Source: Guangjiao Observation
-
On July 15, analysts rated Abbott as a moderate buy but did not include it in the top recommended stocks list. Nevertheless, the robust demand for Abbott's medical devices supports its stock price increase. Source: MarketBeat, with strong demand for medical devices and increased market confidence.
Top Gainers in Pre-Market US Stocks
The Growhub is up 60.83% in pre-market trading. Based on recent news,
-
On July 15, The Growhub Ltd. released original content through the EDGAR system of the U.S. Securities and Exchange Commission, disclosing the company's latest financial and operational information. This announcement triggered a positive market reaction, significantly boosting the stock price.
-
On July 15, The Growhub Ltd.'s announcement indicated that the company made significant progress in financial and operational aspects, enhancing investor confidence and leading to a substantial increase in the stock price during pre-market trading.
-
No other significant recent news. The market reacted positively to the company's announcement, driving the stock price up.
AtaiBeckley is up 34.70% in pre-market trading. Based on recent key news:
-
On July 16, Eli Lilly announced a definitive agreement to acquire AtaiBeckley for $6.75 per share in cash, valuing the equity of the transaction at approximately $2.8 billion. This news significantly boosted AtaiBeckley’s stock price.
-
On July 16, AtaiBeckley’s core product BPL-003 received breakthrough therapy designation from the U.S. FDA and initiated Phase III clinical preparations, enhancing market confidence in its future development.
-
On July 16, AtaiBeckley’s stock price has increased by 31% year-to-date and received "buy" ratings from all 15 brokerages, with a median target price of $14, indicating an optimistic market outlook for its prospects The field of psychotropic drugs attracts the attention of major pharmaceutical companies, and the market is active.
Liminatus Pharma, up 33.01% in pre-market trading, has no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation